They further showed that antagonizing both IL-1 and TNF-α was essential to significantly reduce NF-κB in HSCs and reduce liver fibrosis in a BDL model (no data in the CCl-4 model). The gene discussed is NFKB1; the disease is Hepatic fibrosis.